Novel approaches for vaccine development
Vaccines are critical tools for maintaining global health. Traditional vaccine technologies have been used across a wide range of bacterial and viral pathogens, yet there are a number of examples where they have not been successful, such as for persistent infections, rapidly evolving pathogens with...
Gespeichert in:
| Veröffentlicht in: | Cell 2021-03, Vol.184 (6), p.1589-1603 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1603 |
|---|---|
| container_issue | 6 |
| container_start_page | 1589 |
| container_title | Cell |
| container_volume | 184 |
| creator | Gebre, Makda S. Brito, Luis A. Tostanoski, Lisa H. Edwards, Darin K. Carfi, Andrea Barouch, Dan H. |
| description | Vaccines are critical tools for maintaining global health. Traditional vaccine technologies have been used across a wide range of bacterial and viral pathogens, yet there are a number of examples where they have not been successful, such as for persistent infections, rapidly evolving pathogens with high sequence variability, complex viral antigens, and emerging pathogens. Novel technologies such as nucleic acid and viral vector vaccines offer the potential to revolutionize vaccine development as they are well-suited to address existing technology limitations. In this review, we discuss the current state of RNA vaccines, recombinant adenovirus vector-based vaccines, and advances from biomaterials and engineering that address these important public health challenges.
Vaccines play a critical role in global health, and Gebre et al. review the current state of three vaccine development platforms (mRNA vaccines, vector-based vaccines, and materials science approaches to vaccination). |
| doi_str_mv | 10.1016/j.cell.2021.02.030 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8049514</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0092867421002191</els_id><sourcerecordid>2503446289</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-744c024c104e9cf99340ffa40413c828c72784cbe269a957ea0e1efe489ad2113</originalsourceid><addsrcrecordid>eNp9kEtLAzEQx4Motj6-gAfpsZddJ9lJdwMiSPEFohc9h5idtSnbzZq0Bb-9KdWiF09z-L-GH2NnHHIOfHIxzy21bS5A8BxEDgXssSEHVWbIS7HPhgBKZNWkxAE7inEOAJWU8pANiqJEQIlDNn7ya2pHpu-DN3ZGcdT4MFoba11Ho5qS6PsFdcsTdtCYNtLp9z1mr7c3L9P77PH57mF6_ZhZlHKZlYgWBFoOSMo2ShUITWPSGi9sJSpbirJC-0ZiooySJRkgTg1hpUwtOC-O2dW2t1-9Lai2aTqYVvfBLUz41N44_Vfp3Ey_-7WuAJXkmArG3wXBf6woLvXCxQ0o05FfRS0kFIgTUalkFVurDT7GQM1uhoPeINZzvUnqDWINQifEKXT--8Fd5IdpMlxuDZQwrR0FHa2jzlLtAtmlrr37r_8LMZ-MtA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2503446289</pqid></control><display><type>article</type><title>Novel approaches for vaccine development</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Open Access: Cell Press Free Archives</source><source>EZB Electronic Journals Library</source><creator>Gebre, Makda S. ; Brito, Luis A. ; Tostanoski, Lisa H. ; Edwards, Darin K. ; Carfi, Andrea ; Barouch, Dan H.</creator><creatorcontrib>Gebre, Makda S. ; Brito, Luis A. ; Tostanoski, Lisa H. ; Edwards, Darin K. ; Carfi, Andrea ; Barouch, Dan H.</creatorcontrib><description>Vaccines are critical tools for maintaining global health. Traditional vaccine technologies have been used across a wide range of bacterial and viral pathogens, yet there are a number of examples where they have not been successful, such as for persistent infections, rapidly evolving pathogens with high sequence variability, complex viral antigens, and emerging pathogens. Novel technologies such as nucleic acid and viral vector vaccines offer the potential to revolutionize vaccine development as they are well-suited to address existing technology limitations. In this review, we discuss the current state of RNA vaccines, recombinant adenovirus vector-based vaccines, and advances from biomaterials and engineering that address these important public health challenges.
Vaccines play a critical role in global health, and Gebre et al. review the current state of three vaccine development platforms (mRNA vaccines, vector-based vaccines, and materials science approaches to vaccination).</description><identifier>ISSN: 0092-8674</identifier><identifier>ISSN: 1097-4172</identifier><identifier>EISSN: 1097-4172</identifier><identifier>DOI: 10.1016/j.cell.2021.02.030</identifier><identifier>PMID: 33740454</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenoviridae - genetics ; Animals ; Antigens, Viral - genetics ; Biocompatible Materials ; COVID-19 - prevention & control ; COVID-19 - virology ; COVID-19 Vaccines - immunology ; COVID-19 Vaccines - therapeutic use ; Drug Delivery Systems - methods ; Genetic Vectors - immunology ; Humans ; Immunogenicity, Vaccine ; Liposomes ; mRNA Vaccines ; Nanoparticles ; RNA, Messenger - chemical synthesis ; RNA, Messenger - immunology ; SARS-CoV-2 - immunology ; Vaccines, Synthetic - immunology ; Vaccines, Synthetic - therapeutic use</subject><ispartof>Cell, 2021-03, Vol.184 (6), p.1589-1603</ispartof><rights>2021 Elsevier Inc.</rights><rights>Copyright © 2021 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-744c024c104e9cf99340ffa40413c828c72784cbe269a957ea0e1efe489ad2113</citedby><cites>FETCH-LOGICAL-c455t-744c024c104e9cf99340ffa40413c828c72784cbe269a957ea0e1efe489ad2113</cites><orcidid>0000-0001-8520-2178 ; 0000-0001-9255-5684</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cell.2021.02.030$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33740454$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gebre, Makda S.</creatorcontrib><creatorcontrib>Brito, Luis A.</creatorcontrib><creatorcontrib>Tostanoski, Lisa H.</creatorcontrib><creatorcontrib>Edwards, Darin K.</creatorcontrib><creatorcontrib>Carfi, Andrea</creatorcontrib><creatorcontrib>Barouch, Dan H.</creatorcontrib><title>Novel approaches for vaccine development</title><title>Cell</title><addtitle>Cell</addtitle><description>Vaccines are critical tools for maintaining global health. Traditional vaccine technologies have been used across a wide range of bacterial and viral pathogens, yet there are a number of examples where they have not been successful, such as for persistent infections, rapidly evolving pathogens with high sequence variability, complex viral antigens, and emerging pathogens. Novel technologies such as nucleic acid and viral vector vaccines offer the potential to revolutionize vaccine development as they are well-suited to address existing technology limitations. In this review, we discuss the current state of RNA vaccines, recombinant adenovirus vector-based vaccines, and advances from biomaterials and engineering that address these important public health challenges.
Vaccines play a critical role in global health, and Gebre et al. review the current state of three vaccine development platforms (mRNA vaccines, vector-based vaccines, and materials science approaches to vaccination).</description><subject>Adenoviridae - genetics</subject><subject>Animals</subject><subject>Antigens, Viral - genetics</subject><subject>Biocompatible Materials</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 - virology</subject><subject>COVID-19 Vaccines - immunology</subject><subject>COVID-19 Vaccines - therapeutic use</subject><subject>Drug Delivery Systems - methods</subject><subject>Genetic Vectors - immunology</subject><subject>Humans</subject><subject>Immunogenicity, Vaccine</subject><subject>Liposomes</subject><subject>mRNA Vaccines</subject><subject>Nanoparticles</subject><subject>RNA, Messenger - chemical synthesis</subject><subject>RNA, Messenger - immunology</subject><subject>SARS-CoV-2 - immunology</subject><subject>Vaccines, Synthetic - immunology</subject><subject>Vaccines, Synthetic - therapeutic use</subject><issn>0092-8674</issn><issn>1097-4172</issn><issn>1097-4172</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLAzEQx4Motj6-gAfpsZddJ9lJdwMiSPEFohc9h5idtSnbzZq0Bb-9KdWiF09z-L-GH2NnHHIOfHIxzy21bS5A8BxEDgXssSEHVWbIS7HPhgBKZNWkxAE7inEOAJWU8pANiqJEQIlDNn7ya2pHpu-DN3ZGcdT4MFoba11Ho5qS6PsFdcsTdtCYNtLp9z1mr7c3L9P77PH57mF6_ZhZlHKZlYgWBFoOSMo2ShUITWPSGi9sJSpbirJC-0ZiooySJRkgTg1hpUwtOC-O2dW2t1-9Lai2aTqYVvfBLUz41N44_Vfp3Ey_-7WuAJXkmArG3wXBf6woLvXCxQ0o05FfRS0kFIgTUalkFVurDT7GQM1uhoPeINZzvUnqDWINQifEKXT--8Fd5IdpMlxuDZQwrR0FHa2jzlLtAtmlrr37r_8LMZ-MtA</recordid><startdate>20210318</startdate><enddate>20210318</enddate><creator>Gebre, Makda S.</creator><creator>Brito, Luis A.</creator><creator>Tostanoski, Lisa H.</creator><creator>Edwards, Darin K.</creator><creator>Carfi, Andrea</creator><creator>Barouch, Dan H.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8520-2178</orcidid><orcidid>https://orcid.org/0000-0001-9255-5684</orcidid></search><sort><creationdate>20210318</creationdate><title>Novel approaches for vaccine development</title><author>Gebre, Makda S. ; Brito, Luis A. ; Tostanoski, Lisa H. ; Edwards, Darin K. ; Carfi, Andrea ; Barouch, Dan H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-744c024c104e9cf99340ffa40413c828c72784cbe269a957ea0e1efe489ad2113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenoviridae - genetics</topic><topic>Animals</topic><topic>Antigens, Viral - genetics</topic><topic>Biocompatible Materials</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 - virology</topic><topic>COVID-19 Vaccines - immunology</topic><topic>COVID-19 Vaccines - therapeutic use</topic><topic>Drug Delivery Systems - methods</topic><topic>Genetic Vectors - immunology</topic><topic>Humans</topic><topic>Immunogenicity, Vaccine</topic><topic>Liposomes</topic><topic>mRNA Vaccines</topic><topic>Nanoparticles</topic><topic>RNA, Messenger - chemical synthesis</topic><topic>RNA, Messenger - immunology</topic><topic>SARS-CoV-2 - immunology</topic><topic>Vaccines, Synthetic - immunology</topic><topic>Vaccines, Synthetic - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gebre, Makda S.</creatorcontrib><creatorcontrib>Brito, Luis A.</creatorcontrib><creatorcontrib>Tostanoski, Lisa H.</creatorcontrib><creatorcontrib>Edwards, Darin K.</creatorcontrib><creatorcontrib>Carfi, Andrea</creatorcontrib><creatorcontrib>Barouch, Dan H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cell</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gebre, Makda S.</au><au>Brito, Luis A.</au><au>Tostanoski, Lisa H.</au><au>Edwards, Darin K.</au><au>Carfi, Andrea</au><au>Barouch, Dan H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel approaches for vaccine development</atitle><jtitle>Cell</jtitle><addtitle>Cell</addtitle><date>2021-03-18</date><risdate>2021</risdate><volume>184</volume><issue>6</issue><spage>1589</spage><epage>1603</epage><pages>1589-1603</pages><issn>0092-8674</issn><issn>1097-4172</issn><eissn>1097-4172</eissn><abstract>Vaccines are critical tools for maintaining global health. Traditional vaccine technologies have been used across a wide range of bacterial and viral pathogens, yet there are a number of examples where they have not been successful, such as for persistent infections, rapidly evolving pathogens with high sequence variability, complex viral antigens, and emerging pathogens. Novel technologies such as nucleic acid and viral vector vaccines offer the potential to revolutionize vaccine development as they are well-suited to address existing technology limitations. In this review, we discuss the current state of RNA vaccines, recombinant adenovirus vector-based vaccines, and advances from biomaterials and engineering that address these important public health challenges.
Vaccines play a critical role in global health, and Gebre et al. review the current state of three vaccine development platforms (mRNA vaccines, vector-based vaccines, and materials science approaches to vaccination).</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33740454</pmid><doi>10.1016/j.cell.2021.02.030</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0001-8520-2178</orcidid><orcidid>https://orcid.org/0000-0001-9255-5684</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0092-8674 |
| ispartof | Cell, 2021-03, Vol.184 (6), p.1589-1603 |
| issn | 0092-8674 1097-4172 1097-4172 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8049514 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; Open Access: Cell Press Free Archives; EZB Electronic Journals Library |
| subjects | Adenoviridae - genetics Animals Antigens, Viral - genetics Biocompatible Materials COVID-19 - prevention & control COVID-19 - virology COVID-19 Vaccines - immunology COVID-19 Vaccines - therapeutic use Drug Delivery Systems - methods Genetic Vectors - immunology Humans Immunogenicity, Vaccine Liposomes mRNA Vaccines Nanoparticles RNA, Messenger - chemical synthesis RNA, Messenger - immunology SARS-CoV-2 - immunology Vaccines, Synthetic - immunology Vaccines, Synthetic - therapeutic use |
| title | Novel approaches for vaccine development |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T11%3A54%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20approaches%20for%20vaccine%20development&rft.jtitle=Cell&rft.au=Gebre,%20Makda%20S.&rft.date=2021-03-18&rft.volume=184&rft.issue=6&rft.spage=1589&rft.epage=1603&rft.pages=1589-1603&rft.issn=0092-8674&rft.eissn=1097-4172&rft_id=info:doi/10.1016/j.cell.2021.02.030&rft_dat=%3Cproquest_pubme%3E2503446289%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2503446289&rft_id=info:pmid/33740454&rft_els_id=S0092867421002191&rfr_iscdi=true |